Calcineurin inhibitors are used to stop the working of calcineurin, by binding to protein cells called immunophilins. Calcineurin inhibitors are used topically and systemically to treat various inflammatory skin diseases.
Based on diseases condition, the global calcineurin inhibitor drugs market can be segmented into eczema, psoriasis, ulcerative colitis, and others. The eczema segment is projected to expand at a significant pace during the forecast period, attributed to high prevalence of eczema across the globe. In terms of drug type, the global market can be classified into pimecrolimus, tacrolimus, ciclosporin, tacrolimus, and others. The tacrolimus segment is anticipated to expand at a high CAGR from 2018 to 2026, as most doctors prefer to use tacrolimus because it penetrates the cutaneous barrier of the skin to a much greater extent, resulting in effective outcome. Based on dosage form, the global calcineurin inhibitor drugs market can be bifurcated into topical and oral. The topical segment is likely to expand at a rapid pace during the forecast period, because topical form of drug does not cause skin atrophy and absorption through the skin is minimal. In terms of distribution channel, the global market can be divided into hospital pharmacies, retail pharmacies, and others. The retail pharmacies segment is expected to expand at a high CAGR from 2018 to 2026, as skin diseases are mostly treated in independent clinics such as skin centers and patients feel convenient to purchase drugs through retail pharmacies. Moreover, usage of the drug does not require strict supervision.
Rise in prevalence of atopic dermatitis is a major factor fueling the global calcineurin inhibitor drugs market. Moreover, rise in awareness and availability of new formulation drugs are projected to drive the market during the forecast period. However, side effects of the drugs such as gastrointestinal disturbances, nephrotoxicity, and skin burning are projected to restrain the market in the next few years.
In terms of region, the global calcineurin inhibitor drugs market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global market. The region is projected to account for a significant share of the global market during the forecast period, due to rise in prevalence of atopic dermatitis in children. According to a report published in the journal Dermatology Clinics 2017, about 6% to 12% children were affected with atopic dermatitis in the U.S. Rosacea diseases is a major concern in countries in Europe. According to the Journal of the European Academy of Dermatology and Venereology, prevalence of rosacea skin disease in Germany was 12% in 2016 and is likely to increase in the near future. This factor is projected to drive the calcineurin inhibitor drugs market in Europe. Rise in prevalence of psoriasis, and increase in awareness about psoriasis among health care providers and society in the region are anticipated to fuel the growth of the market in Asia Pacific during the forecast period. Rise in prevalence of skin diseases such as infantile acropustulosis, psoriasis, and papular urticaria in Central Africa is likely to augment the calcineurin inhibitor drugs market in Middle East & Africa 2018 to 2026.
Key players operating in the global calcineurin inhibitor drugs market are Novartis AG, AbbVie Inc., Astellas Pharma, and Pfizer, Inc., among others.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.